



GAU 1646

Attorney's Docket No: L0461/7104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Luiten et al.
Serial No. : 09/766,889
Filed : January 19, 2001
For : MAGE ANTIGENIC PEPTIDES WHICH BIND HLA-B35 and HLA-B44
Examiner : Unknown
Art Unit : 1646


TECH CENTER 1600/2900

AUG 14 2001

RECEIVED

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 8th day of August, 2001.


Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:


- ☒ Information Disclosure Statement
- ☒ Form PTO-1449 and References Cited
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No check is enclosed. If a fee is determined to be required, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:


John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. L0461/7104
Dated: August 8, 2001
xNDD



Attorney's Docket No: L0461/7104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Luiten et al.
Serial No. : 09/766,889
Filed : January 19, 2001
For : MAGE ANTIGENIC PEPTIDES WHICH BIND HLA-B35 and HLA-B44
Examiner : Unknown
Art Unit : 1646

TECH CENTER 1600/2900

AUG 14 2001

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 8th day of August, 2001.


Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

☒ [X] This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

☒ [X] The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

☐ [] The Applicant hereby makes the following additional information of record in the above-identified application.

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

The following are remarks concerning the other information cited:

PART IV: Remarks

Documents cited on the attached form PTO-1449 (modified) are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: 
John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. L0461/7104
Dated: August 8, 2001
xNDD

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/766,889	ATTY. DOCKET NO.: L0461/7104
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: January 19, 2001	
		APPLICANT: Luiten et al.	
		GROUP ART UNIT: 1646	EXAMINER: Unknown
Sheet	I	of	

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A12	5,821,122		Lucas et al.	10-13-1998
	A13	5,554,506		Boon-Falleur et al.	09-10-1996
	A14	5,462,871		Boon-Falleur et al.	10-31-1995

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B2	EP	1 025 849	A1	Ludwig Institute for Cancer Research	08-09-2000	
	B3	WO	99/37665	A1	Ludwig Institute for Cancer Research	07-29-1999	
	B4	WO	97/31017	A1	Ludwig Institute for Cancer Research	08-28-1997	
	B5	WO	97/10837	A1	Ludwig Institute for Cancer Research	03-27-1997	
	B6	WO	96/26214	A1	Ludwig Institute for Cancer Research	08-29-1996	
	B7	WO	92/20356	A1	Ludwig Institute for Cancer Research	11-26-1992	
	B8	WO	98/58951	A1	Ludwig Institute for Cancer Research	12-30-1998	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C22	SCHULTZ et al., <i>Tissue Antigens</i> 57(2):103-109 (2001)		
	C23	LUITEN et al., <i>Tissue Antigens</i> 56(1):77-81 (2000)		
	C24	VALMORI et al., <i>J. Exp. Med.</i> 189(6): 895-905 (1999)		
	C25	VALMORI et al., <i>J. Immunol.</i> 164: 1125-1131 (2000)		

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.